| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IHL Stock Overview
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia.
Incannex Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.28 |
| 52 Week High | AU$0.76 |
| 52 Week Low | AU$0.18 |
| Beta | 2.47 |
| 1 Month Change | 16.67% |
| 3 Month Change | -23.29% |
| 1 Year Change | 1.82% |
| 3 Year Change | 221.84% |
| 5 Year Change | 1,300.00% |
| Change since IPO | 221.84% |
Recent News & Updates
Shareholder Returns
| IHL | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 40.0% | 4.3% | 0.7% |
| 1Y | 1.8% | -11.5% | -8.0% |
Return vs Industry: IHL exceeded the Australian Pharmaceuticals industry which returned -11.5% over the past year.
Return vs Market: IHL exceeded the Australian Market which returned -8% over the past year.
Price Volatility
| IHL volatility | |
|---|---|
| IHL Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 12.2% |
| Market Average Movement | 10.5% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 4.6% |
Stable Share Price: IHL is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: IHL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 3 | Joel Latham | https://www.incannex.com.au |
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company’s products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases.
Incannex Healthcare Limited Fundamentals Summary
| IHL fundamental statistics | |
|---|---|
| Market Cap | AU$333.41m |
| Earnings (TTM) | -AU$12.80m |
| Revenue (TTM) | AU$720.43k |
500.0x
P/S Ratio-28.1x
P/E RatioIs IHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IHL income statement (TTM) | |
|---|---|
| Revenue | AU$720.43k |
| Cost of Revenue | AU$548.32k |
| Gross Profit | AU$172.11k |
| Other Expenses | AU$12.97m |
| Earnings | -AU$12.80m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 23.89% |
| Net Profit Margin | -1,776.19% |
| Debt/Equity Ratio | 0.0% |
How did IHL perform over the long term?
See historical performance and comparison